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ABSTRACT
Background: There are still substantial uncertainties over best practice in delirium care. The European
Delirium Association (EDA) conducted a survey of its members and other interested parties on various
aspects of delirium care.
Methods: The invitation to participate in the online survey was distributed among the EDA membership. The
survey covered assessment, treatment of hyperactive and hypoactive delirium, and organizationalmanagement.
Results: A total of 200 responses were collected (United Kingdom 28.6%, Netherlands 25.3%, Italy 15%,
Switzerland 9.7%, Germany 7.1%, Spain 3.8%, Portugal 2.5%, Ireland 2.5%, Sweden 0.6%, Denmark
0.6%, Austria 0.6%, and others 3.2%). Most of the responders were doctors (80%), working in geriatrics
(45%) or internal medicine (14%). Ninety-two per cent of the responders assessed patients for delirium
daily. The most commonly used assessment tools were the Confusion Assessment Method (52%) and
the Delirium Observation Screening Scale (30%). The first-line choice in the management of hyperactive
delirium was a combination of non-pharmacological and pharmacological approaches (61%). Conversely,
non-pharmacological management was the first-line choice in hypoactive delirium (67%). Delirium awareness
(34%), knowledge (33%), and lack of education (13%) were the most commonly reported barriers to
improving the detection of delirium. Interestingly, 63% of the responders referred patients after an episode of
delirium to a follow-up clinic.
Conclusions: This is the first systematic survey involving an international group of specialists in delirium.
Several areas of lack of consensus were found. These results emphasise the importance of further research to
improve care of this major unmet medical need.
Key words: delirium, European Delirium Association, delirium knowledge, survey, clinical practice
Correspondence should be addressed to: Dr Alessandro Morandi, MD, MPH
Via Aselli 16, Cremona, 26100, Italy. Phone: +39-03725357753; Fax:
+39-03725357705. Email: morandi.alessandro@gmail.com. Received 18May
2013; revision requested 9 Jun 2013; revised version received 11 Jul 2013;
accepted 12 Jul 2013. First published online 20 August 2013.
Introduction
Delirium is an acute neuropsychiatric disorder
characterized by inattention, other cognitive
impairments, and disturbances in consciousness.
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It has a prevalence ranging from 9% to 80%
depending on the setting (Inouye et al., 1999; Ely,
2001; Ouimet et al., 2007; Ryan et al., 2013).
Delirium is independently associated with increased
length of stay, increased hospital costs, higher
mortality, and it is a risk factor for permanent
cognitive impairment (Fong et al., 2009; Girard
et al., 2010; National Institute for Health and
Clinical Excellence (NICE), 2010; Witlox et al.,
2010; Davis et al., 2012) It is often highly distressing
for patients and carers (Partridge et al., 2013).
Several studies have demonstrated that delirium is
partially preventable (National Institute for Health
and Clinical Excellence, 2010).
Despite its high prevalence and seriousness,
delirium is substantially under-detected (Collins
et al., 2010), there are no licensed pharmacological
treatments, and few national guidelines exist
(National Institute for Health and Clinical
Excellence, 2010). The European Delirium Asso-
ciation (EDA; www.europeandeliriumassociation.
com) was established in 2006 with the main aims
of promoting knowledge of delirium, improving
clinical management, and providing support for
research within Europe. The American Delirium
Society (ADS; www.americandeliriumsociety.org)
was recently created with similar goals, underlining
the importance of coordinating clinical and research
efforts to reduce the impact of delirium on short-
and long-term health outcomes.
Several surveys have been conducted to evaluate
the knowledge of healthcare providers with respect
to delirium (Ely et al., 2004; Fang et al., 2008; Van
Eijk et al., 2008; Cadogan et al., 2009; Davis and
MacLullich, 2009; Patel et al., 2009; Ceraso et al.,
2010; Forsgren and Eriksson, 2010; Mac Sweeney
et al., 2010; Devlin et al., 2011). Four of these
were conducted within Europe, one in the United
States, two in South America, and one across
different countries. In addition, a European survey
(Leentjens et al., 2008) was carried out to investig-
ate the existence and contents of different delirium
guidelines across national psychiatric associations.
However, no survey has specifically targeted
an international group of specialists involved in
delirium care and clinical practice, and uncertainties
still exist on the optimal management of delirium.
Since previous surveys were conducted,
guidelines on delirium practice (National Institute
for Health andClinical Excellence, 2010) have been
published by a national body within a European
country (UK NICE). We were interested in
surveying European clinicians with special interest
in delirium to assess possible variation in practice.
Our main areas of interest were assessment and
diagnosis, treatment of hyperactive and hypoactive
delirium, and organizational management.
Methods
Survey development and design
The questionnaire was constructed through an
iterative process, which included item generation,
construction, pilot testing, and refinement from
expert members on the EDA Board. The final
survey consisted of 53 questions organized into
four different sections: assessment and diagnosis of
delirium, treatment of hyperactive delirium, treat-
ment of hypoactive delirium, and organizational
management of delirium care (Appendix A for
the full questionnaire) (see Appendixes A and B,
available as supplementary material attached to the
electronic version of this paper at www.journals.
cambridge.org/jid_IPG).
Survey administration
The survey period was 24 March 2012 to
11 July 2012. The invitation to participate in the
online survey was distributed among the EDA
membership, with additional publication on the
EDA website. Reminders were sent out at one and
two months after the initial survey distribution.
Responses were anonymized.
Statistical analysis
Variables were summarized using median and
interquartile range (IQR) for continuous variables
or proportions for categorical variables. For the
purpose of the analysis, we defined experts in
delirium management as those responders who (1)
scored 8/10 in the self-report question: “How
would you rate your knowledge of delirium”; and
(2) gave a response of “more than sufficient” to the
question: “How much training you have received
on delirium management.” The χ2 test was used
to compare responses to questions on delirium
assessment, and management of hyperactive and
hypoactive delirium in delirium experts compared
to the other responders.
Results
Characteristics of the responders
A total of 200 responses were collected. The
majority of responders were doctors (67%),
followed by nurses (14%). Respondents were
mainly from European countries (United Kingdom
28.6%, Netherlands 25.3%, Italy 15%, Switzerland
9.7%, Germany 7.1%, Spain 3.8%, Portugal
2.5%, Ireland 2.5%, Sweden 0.6%, Denmark
0.6%, Austria 0.6%, United States 1.3%, Canada
0.6%, and Australia 0.6%). Most doctors worked
in geriatric medicine (45%) and internal/acute
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Table 1. Characteristics of responders
VARIABLEa N = 200
............................................................................................................................................................................................................................................................................................................................
Main occupation
Doctor 135 (67%)
Nurse 29 (14%)
Others 36 (18%)
Duration of practice
Over 20 years 20 (25%)
10–19 years 50 (34%)
5–9 years 45 (30%)
1–4 years 11 (7%)
<1 year 3 (2%)
Training received on delirium management
None 5 (3%)
Very little 17 (11%)
Some but sufficient 17 (11%)
Sufficient 80 (50%)
More than sufficient 39 (25%)
Where you have received your formal training in delirium management?
Medical school 15 (10%)
Nursing school 13 (2%)
Postgraduate education 90 (58%)
Professional conferences 47 (30%)
Where is your setting of practice?
General hospital 11 (6.7%)
General hospital affiliated to university 76 (46%)
University hospital 40 (24%)
General practice/community 10 (6%)
Others 28 (17%)
Specific setting of practice
Geriatrics 97 (45%)
Internal medicine/acute medicine 30 (14%)
Internal medicine specialties 9 (4%)
Intensive care unit 17 (9%)
Emergency medicine 4 (2%)
Nursing home 4 (2%)
Old age psychiatry 24 (11%)
Palliative care 8 (4%)
Notes: aThe different total numbers in this table are due to the inability to gather a 100% response rate on each question.
medicine (14%), followed by old age psychiatry
(11%), intensive care units (9%), and internal
medicine specialties (4%; Table 1). Seventy per
cent of the responders worked in a university
hospital or general hospital affiliated to a university.
Only 11.9% had received training on delirium
management during their undergraduate medical or
nursing school training. However, 75% rated their
knowledge of delirium management as sufficient or
more than sufficient.
Assessment and diagnosis of delirium
Ninety-two per cent of responders reported that
they assessed patients for delirium in their daily
clinical practice. Several scales were used to assess
delirium, including the Confusion Assessment
Method (CAM) (52%), the Delirium Observation
Screening Scale (DOSS) (30%), the CAM for
the Intensive Care Unit (CAM-ICU) (13%), the
Delirium Rating Scale-Revised 98 (DRS-R-98)
(10%), 4 A’s Test (4AT) (2%), the Cognitive
Test for Delirium (0.5%), and others (4%)
(Table 2). The final diagnosis was most frequently
made (63.2%) using the Diagnostic and Statistical
Manual of Mental Disorders-IV (DSM-IV), and
the rest using the International Classification of
Diseases-10. Once a diagnosis was made, 43.4%
of the responders repeated the assessment at least
once a day, with 19% twice a day, and 18.5% up to
three times a day. Most of the time, the diagnosis of
delirium was included in the information discharge
records (91.3%).
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Table 2. Assessment and diagnosis of delirium
VARIABLEa
............................................................................................................................................................................................................................................................................................................................
Do you assess for delirium in your daily practice?
Yes 184 (92%)
No 16 (8%)
How often you use a scale to assess for delirium?
Always 21 (26%)
Most of the time 51 (26%)
About half of the time 24 (12%)
Infrequently 44 (22%)
Never 29 (15%)
What tools do you use to assess for delirium?b
Confusion Assessment Method 104 (52%)
Delirium Observation Screening Scale 60 (30%)
Confusion Assessment Method-ICU 26 (13%)
Delirium Rating Scale-Revised 98 20 (10%)
4AT 4 (2%)
Cognitive Test for Delirium 1 (0.5%)
Otherc 7 (4%)
If patients are diagnosed with delirium, how often would you review their status?
Once a day 82 (43%)
Twice a day 36 (19%)
Three times a day 35 (19%)
More than three times a day 9 (5%)
Other 27 (14%)
Notes: aThe different total numbers in this table are due to the inability to gather a 100% response rate on each question.
bEach respondent could use more than one scale.
cOther (tools): Mini Mental State Examination, counting backwards, Delirium-O-Meter, Memorial Delirium Assessment Scale, Richmond
Agitation and Sedation Scale.
Management of hyperactive delirium
A combination of non-pharmacological and phar-
macological strategies was the dominant approach
to the management of hyperactive delirium (60.6%,
N = 103), while 30% (N = 51) used only a
non-pharmacological protocol and 9.4% (N = 16)
adopted a purely pharmacological management. A
drug for the treatment of agitation in hyperactive
delirium was used by 60% of the responders.
Haloperidol was the most widely used antipsychotic
(62%, N = 92), followed by risperidone (12%,
N = 18), clozapine (5%, N = 7), and others (21%,
N = 148) (Appendix B1). The most common
starting dose for haloperidol was 0.5 mg (49%),
with a frequency of twice a day (42%), and mainly
through an oral route (76.9%) (Appendix B2). The
common starting dose for risperidone was 0.5 mg
(39%, N = 7). Only 61% routinely evaluated the
QTc interval on the electrocardiography (ECG)
before an antipsychotic was prescribed (Appendix
B4). Most of the responders continued (27%,
N = 32) the pharmacological treatment until
delirium resolution, although we found a wide
variation in the duration of treatment ranging from
1–2 days (6%, N = 7) to >8 days (6%, N =
7) (Appendix B5). A variety of interventions were
included in the non-pharmacological management
of hyperactive delirium (Figure 1); the most
common were the evaluation of common causes
of delirium (81.9%, N = 163), pain evaluation
and treatment (80.4%, N = 160), assessment of
constipation and urinary retention (78%, N= 156),
and sensory aids (72.3%, N = 144).
Management of hypoactive delirium
A non-pharmacological approach was the most
commonly reported way of managing hypoactive
delirium (67.5%, N = 108), followed by
a combination of pharmacological and non-
pharmacological (29.4%, N = 47) and pure
pharmacological (3%; N = 5) strategies. As
with the management of hyperactive delirium, in
the non-pharmacological protocol, a wide variety
of interventions were employed: evaluation of
common causes of delirium (76.5%, N = 153),
pain evaluation and treatment (71.5%, N = 143),
assessment of constipation and urinary retention
(71%, N = 142), and sensory aids (70%, N = 140)
being the most prominent interventions (Figure 1).
In the instances where a drug was prescribed (N
= 67), the first choice was haloperidol (46%, N
= 31), followed by risperidone (16%, N = 11),
rivastigmine (7%, N = 5), and others (31%, N =
30) (Appendix B).
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Figure 1. Interventions for the management of hyperactive (panel A) and hypoactive (panel B) delirium.
Delirium work-up
In terms of investigations, doctors frequently
ordered laboratory analyses (58.5%), and
neuroimaging studies such as brain CT
(26.5%) and MRI (26.5%). Less frequently,
electroencephalogram (9.5%) and lumbar
punctures (6%) were performed to investigate
the causes of delirium.
Organizational management
A minority of the responders either agreed (41.7%)
or strongly agreed (4%) that delirium was well
managed in the clinical setting where they worked.
Eighty per cent of the participants believed
that delirium is under-detected in their setting.
However, the majority (78%) reported that their
institutions had specific guidelines for delirium.
Delirium awareness (34%), knowledge/
incompetence (33%), lack of education (13.2%),
and lack of time for assessment (8.8%) were
identified as the four main barriers to improving
delirium detection (Appendix B6). Similarly, poor
knowledge (24.4%), staffing issues (24.4%), poor
education (13.3%), and poor attitudes (4.5%)
were the main barriers to improving delirium
management (Appendix B7).
After discharge, follow-up was performed by
63% of the responders. Specifically, 15.3% assessed
only those patients being discharged to home,
18.5% referred patients to a memory clinic if
either the cognitive impairment did not resolve
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or there was a pre-existing cognitive impairment
(10.6%), and 11.9% assessed regardless of cognitive
impairment at discharge. Interestingly, 6.6% of
the participants reported a referral to a dedicated
delirium follow-up clinic.
Comparison of delirium management
between experts and non-experts
Within the sample, there were 67 participants who
could be identified as being experts in delirium
care. Compared to the rest of the sample, these
experts were more likely to use haloperidol as a
first-line drug for the management of agitation in
hyperactive delirium (p = 0.010) and to use a non-
pharmacological intervention as the first approach
for the management of hypoactive delirium (p =
0.01) (Appendix B8). No other significant
differences were detected in the use of drugs or
approach to the management of hyperactive and
hypoactive delirium.
Discussion
This is the first international survey of practice
among professionals with an interest in delirium.
The survey found areas of both agreement and
disagreement. There was substantial consensus in
many aspects of the assessment and management of
hyperactive and hypoactive delirium. In particular,
the majority stated that they assessed for delirium
frequently and this information is included in the
medical records. A large proportion of clinicians
reported using a non-pharmacological approach
alone or combined with a pharmacological
intervention to manage hyperactive delirium. There
is inconsistency on the use of antipsychotic drugs
to decrease symptoms of agitation in hyperactive
delirium, although haloperidol was the most
frequently used drug for this purpose. Interestingly,
about half of the clinicians start with a low dose,
using an oral route in almost 80% of the patients.
Similarly, the management of hypoactive delirium
is mainly approached with non-pharmacological
strategies and rarely by pharmacological treatments.
However, only 61% of the responders routinely
used ECG in the context of antipsychotic
prescription, despite this being recommended by
guidelines. Finally, delirium experts reported a
significantly higher proportion of haloperidol use
as a first-line treatment of hyperactive delirium
and a non-pharmacological approach as the first
intervention for the management of hypoactive
delirium.
In 2010, NICE published the first national
guidelines on delirium diagnosis, prevention,
and management (National Institute for Health
and Clinical Excellence, 2010). These guidelines
recommended that the short version of the CAM
and the CAM-ICU (for critical care patients)
could be used as alternatives to DSM-IV to
diagnose delirium. This is in accordance with
our findings, given that 52% used the CAM and
13% used the CAM-ICU. Interestingly we also
found that 30% of the responders used the DOSS
for delirium screening. All the responders in our
survey performed the final diagnosis according to
standard diagnostic criteria, using either the DSM-
IV (63.2%) or the ICD-10 (36.8%).
The NICE guidelines (National Institute for
Health and Clinical Excellence, 2010) provided re-
commendations on non-pharmacological and phar-
macological interventions for delirium treatment,
without differentiating between the hyperactive
and hypoactive form. The guidelines suggested
that first there should be a non-pharmacological
approach, identifying and managing underlying
causes, providing reorientation, and involving
family and carers. In this survey, respondents were
more aligned with these guidelines in the case
of hypoactive delirium, with a 67.5% prevalence
of an exclusively non-pharmacological intervention
and a 29% prevalence of a mixed approach,
i.e. pharmacological and non-pharmacological.
With hyperactive delirium, there was a higher
prevalence of the mixed approach (60.6%) and a
lower prevalence of the pure non-pharmacological
management (30%). These findings suggest that
drugs are commonly used in the initialmanagement
of both hypoactive and hyperactive delirium. This
indicates substantial divergence from the evidence-
based recommendations in the NICE guidelines,
since the NICE guidelines only support the use of
haloperidol or olanzapine to control patients who
are considered at risk for themselves or others and
when a non-pharmacological approach (i.e. verbal
and non-verbal techniques) have failed.
In our survey, haloperidol was the first-line
drug used to treat hyperactive delirium despite
its unproven efficacy and the absence of official
bodies’ approval for this indication and as recently
reported by Meagher and colleagues (2013). The
findings of haloperidol being the most frequently
prescribed drug are in line with previous surveys
in ICU and non-ICU settings (Ely et al., 2004;
Fang et al., 2008; Van Eijk et al., 2008; Cadogan
et al., 2009; Davis and MacLullich, 2009; Patel
et al., 2009; Ceraso et al., 2010; Forsgren and
Eriksson, 2010; Mac Sweeney et al., 2010; Devlin
et al., 2011). The type of antipsychotics reported
in our survey also confirms the data reported by
Meagher (2010) on delirium experts attending a
workshop of the EDA, organized to explore the
attitude toward delirium pharmacotherapy. In fact,
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about 66% of the participants to the workshop
indicated haloperidol as their first choice to treat
delirium. The information on the suggested daily
dose (0.5–15 mg/day) cannot directly be compared
to our data because we gathered information on
the starting dose. The higher doses reported by
Meagher (2010) might also have been related to
a higher prevalence of ICU healthcare providers in
the workshop audience.
Interestingly, about 32% of the responders
continued pharmacological treatment until delirium
resolution. The use of antipsychotics until delirium
resolution might reflect the indications of the
NICE guidelines, which support a treatment for
one week or less. Nonetheless, about 12% of
the responders use a pharmacological treatment
“as long as required.” This approach could
be supported by the persistence of delirium in
about 17% of elderly patients discharged from
hospital after acute hospitalization (Cole et al.,
2009). Nonetheless, antipsychotics are used for the
treatment of symptoms of agitation in delirium and
there is no clear indication for their use in the
hypoactive delirium. The continuation of treatment
might indeed expose hospitalized patients to a
higher risk of cardiovascular events and mortality,
especially in older patients having pre-existing
dementia (Maher et al., 2011).
The NICE guidelines (National Institute for
Health and Clinical Excellence, 2010) reported
information only on extrapyramidal signs as side
effects of antipsychotics, but there is no mention
on the cardiac effects and the need for ECG
monitoring. We did not investigate in our survey
the use of specific scales to measure extrapyramidal
side effects, but we did gather information on the
ECG monitoring. There have been cases of QTc
prolongation and torsades de pointes (TdP) after
high doses of intravenous (IV) administration of
haloperidol, and it has been suggested that patients
receiving low doses (<2 mg per day) of haloperidol
with no risk factors for prolonged QTc or TdP,
and with a normal QTc on a baseline ECG should
not receive continuous ECG monitoring (Meyer-
Massetti et al., 2010). If cumulative doses are
>2 mg per day, patients should be placed on
telemetry (Meyer-Massetti et al., 2010). In our
studied population we found that most of the
responders use an oral route (76.9%), followed
by IV administration when haloperidol is used.
Interestingly, 34% perform an ECG evaluation or
a single rhythm strip before starting the drug and
6.3% performed continuous heart monitoring. The
latter may reflect the presence of ICU physicians in
the responders’ group.
Another key point is the difference in strategies
for investigation of delirium. Currently, there
are no specific indications on the type and
sequence of tests for the evaluation of patients
with delirium. We found that doctors frequently
order laboratory analyses to rule out the causes
of delirium, which reflect a reasonable approach
since an infection or electrolyte unbalances are
frequent triggers. However, little is known on the
risk and benefit of ordering instrumental tests
(i.e. neuroimaging, electroencephalogram (EEG),
or lumbar punctures) (Morandi et al., 2010).
Unnecessary tests might be detrimental for the
patients, possibly leading to an increased severity
of delirium and exposing the patients to a greater
risk of complications. If delirium affects one in five
patients (Inouye et al., 1999; Ely, 2001; Ouimet
et al., 2007; Ryan et al., 2013), deciding who with
delirium should receive an instrumental evaluation
is extremely important also for the rational use of
healthcare resources.
Interestingly, neither the NICE guidelines nor
previous surveys have mentioned follow-up after
an episode of delirium, although it has been
reported an association between delirium, cognitive
impairment, and worsening dementia. (Fong
et al., 2009; Girard et al., 2010; Davis et al.,
2012). In our cohort of responders, we found
different approaches but most importantly 60% of
responders follow up patients after an episode of
delirium, and even more interestingly, in almost 7%
of the cases there are dedicated delirium follow-
up clinics. The importance of referring patients
with cognitive impairment/dementia to a memory
clinic has been shown previously (Morgan et al.,
2009). Early detection of dementia is critical to
ensuring that persons having dementia and their
caregivers have access to treatment, education,
counseling, and other services that can delay
decline, prevent crises, ease caregiver burden, and
delay institutionalization. At the same time, the
establishment of follow-up clinics also provides
the opportunity to identify potentially treatable
causes in patients for whom delirium resolves before
hospital discharge and for those with persistent
delirium.
Another important domain of the survey was the
assessment of the perceived barriers to improve the
education and management of delirium. Improve-
ment of education and management of delirium
is limited, as we found by both individual level
barriers and organizational/cultural barriers. This
concept has been introduced by Teodorczuk and
colleagues (2012) after conducting two workshops
within two EDA meetings in 2010 and 2011 to
specifically identify what are the main barriers to
improve the detection of delirium and to provide a
“call for action” plan at individual, organizational,
and societal levels to improve recognition.
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The principal way in which this survey
differs from previous work is in the choice
of respondent population, a group of specialist
delirium practitioners. Other surveys on delirium
diagnosis and management have mainly been of
healthcare providers working in an ICU (Ely et al.,
2004; Van Eijk et al., 2008; Cadogan et al., 2009;
Patel et al., 2009; Ceraso et al., 2010; Forsgren and
Eriksson, 2010;Mac Sweeney et al., 2010), focusing
on tools to assess for delirium, sedation practice,
and the pharmacological management of delirium.
Haloperidol was reported as the most commonly
used drug to treat delirium, and the CAM-ICU was
the most frequently used tool to assess for delirium,
followed by the Intensive Care Delirium Screening
Checklist. Two other surveys have targeted
ICU pharmacists and junior doctors (Davis and
MacLullich, 2009; Devlin et al., 2011). The survey
of pharmacists (Devlin et al., 2011) specifically
reported on the pharmacological treatment of
delirium, and practice with regard to the safety
of treatment with ECG monitoring. The survey of
junior UK doctors (Devlin et al., 2011) identified
gaps in confidence in diagnostic and management
skills with respect to delirium. In each of these
surveys, consistent with our findings, haloperidol
was reported as the first-line treatment of delirium.
To our knowledge this is the first online survey
to explore attitudes of delirium recognition and
management in a healthcare providers with a special
interest in delirium. Nonetheless, several limitations
should be mentioned. We were able to obtain a high
level of responses mainly from just six European
countries (United Kingdom, Netherlands, Italy,
Spain, and Switzerland). The lower rate of
responses from other countries might reflect our
inability to reach providers with an interest in
delirium or it may simply reflect an increased
level of interest in delirium in these particular
countries. The second important limitation was
the inability to gather a 100% response rate on
each question. The third limitation relates to the
possible contrast between self-report practice and
actual practice, and this could be the base for future
quality improvement projects. Finally, we have not
addressed which are the main interventions for the
prevention of delirium. This information should be
included in future investigations.
In conclusion, this is the first survey involving an
international group of professionals with a special
interest in delirium care. Across different responses,
we found areas of both common practice and lack
of consensus (i.e. initial drug use, delirium work-
up evaluation, post-delirium follow-up), underlying
the gaps between clinical guidelines recommenda-
tions and clinical practice. These issues highlight
areas of future research, including syntheses of
existing evidence, the opportunity to monitor
temporal trends and to detect future changes of
practice, and to provide key elements to support
further education on the emerging topic of delirium.
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